CN Stock MarketDetailed Quotes
600223 Lushang Freda Pharmaceutical
- 7.32
- -0.14-1.88%
Market Closed Dec 13 15:00 CST
7.44BMarket Cap31.42P/E (TTM)
7.45High7.29Low152.30KlotVolume7.45Open7.46Pre Close112.16MTurnover1.50%Turnover Ratio24.56P/E (Static)1.02BShares10.0952wk High1.84P/B7.44BFloat Cap5.6952wk Low8.21Limit Up1.02BShs Float18.64Historical High6.71Limit Down2.15%Amplitude1.32Historical Low0.15Dividend TTM7.36Avg Price92.56KlotAsk2.05%Div YieldTTM100Lot Size57.19KlotBid
Lushang Freda Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -17.45%2.8B | -22.15%1.93B | -29.99%890.64M | -64.65%4.58B | -60.20%3.39B | -48.85%2.47B | -14.17%1.27B | 4.76%12.95B | 34.33%8.53B | 18.88%4.84B |
| Operating revenue | -17.45%2.8B | -22.15%1.93B | -29.99%890.64M | -64.65%4.58B | -60.20%3.39B | -48.85%2.47B | -14.17%1.27B | 4.76%12.95B | 34.33%8.53B | 18.88%4.84B |
| Other operating revenue | ---- | -48.65%19.57M | ---- | -76.90%67.66M | ---- | -58.54%38.11M | ---- | 80.96%292.87M | ---- | 63.65%91.91M |
| Total operating cost | -18.66%2.61B | -24.15%1.78B | -32.38%833.25M | -64.92%4.37B | -61.03%3.21B | -48.81%2.35B | -12.12%1.23B | 7.14%12.45B | 43.21%8.23B | 23.72%4.59B |
| Operating cost | -24.88%1.35B | -32.89%926.71M | -43.21%437.84M | -74.89%2.45B | -71.50%1.8B | -58.67%1.38B | -11.75%771.02M | 6.23%9.76B | 46.23%6.3B | 19.28%3.34B |
| Operating tax surcharges | 17.56%28.42M | 47.72%19.67M | 801.60%9.36M | -93.25%36.42M | -94.41%24.17M | -94.69%13.32M | -101.69%-1.33M | -8.32%539.39M | 44.54%432.44M | 32.47%250.91M |
| Operating expense | -6.03%1.02B | -2.58%700.16M | 0.97%322.98M | 10.12%1.45B | 12.26%1.09B | 7.76%718.67M | 7.86%319.86M | 4.79%1.31B | 20.57%968.99M | 35.95%666.93M |
| Administration expense | -24.19%119.21M | -27.52%78.94M | -38.10%36.82M | -36.29%222.98M | -30.39%157.25M | -22.75%108.91M | -20.99%59.47M | -7.87%349.98M | -9.57%225.88M | -20.05%140.99M |
| Financial expense | -136.66%-14.85M | -113.79%-8.72M | -112.44%-6.63M | -83.81%57.07M | -81.34%40.51M | -53.59%63.2M | -4.12%53.3M | 287.97%352.54M | 19,856.64%217.05M | 4,985.90%136.2M |
| -Interest expense (Financial expense) | -73.09%18.31M | -81.23%15.36M | -91.22%5.02M | -76.37%94.75M | -73.23%68.03M | -42.44%81.82M | -21.24%57.16M | 257.00%400.97M | 811.14%254.08M | 861.25%142.16M |
| -Interest Income (Financial expense) | -10.30%-33.38M | -14.16%-24.09M | -55.20%-11.88M | 5.18%-44.95M | 8.40%-30.27M | 10.76%-21.1M | 56.48%-7.65M | -24.00%-47.4M | -24.66%-33.04M | -29.65%-23.64M |
| Research and development | 3.31%103.8M | 1.35%65.65M | 10.09%32.89M | 14.52%153.36M | 27.11%100.47M | 17.94%64.77M | 33.72%29.88M | 12.77%133.92M | -1.63%79.04M | 8.04%54.92M |
| Credit Impairment Loss | 25.97%-21.88M | 48.69%-14.4M | -366.63%-1.91M | 55.69%-29.63M | -90.94%-29.55M | -61.91%-28.07M | -217.42%-409.71K | 33.83%-66.86M | 66.15%-15.48M | 65.05%-17.34M |
| Asset Impairment Loss | -729.14%-4.75M | -379.91%-2.74M | ---- | 94.07%-15.92M | -162.76%-573.33K | -162.42%-570.17K | ---- | -37.22%-268.33M | 175.63%913.48K | 412.23%913.48K |
| Other net revenue | -70.60%47.64M | -72.79%40.68M | -82.94%22.85M | 207.86%207.21M | 79.91%162.06M | 168.89%149.53M | 496.84%133.94M | -186.18%-192.12M | 27.27%90.08M | 29.54%55.61M |
| Invest income | -72.46%48.36M | -76.63%38.93M | -88.50%14.66M | 84.45%214.34M | 109.37%175.58M | 184.36%166.59M | 778.25%127.44M | -42.28%116.21M | -16.20%83.86M | -29.60%58.59M |
| -Including: Investment income associates | -5.60%45.53M | -8.01%36.1M | 44.80%14.54M | -34.85%72M | -38.46%48.23M | -26.10%39.25M | 11.17%10.04M | -44.96%110.51M | -21.64%78.37M | -36.15%53.11M |
| Asset deal income | 548.40%1.16M | 10,462.82%1.12M | 3,486.04%526.18K | -200.61%-773.78K | -137.26%-258.99K | -98.48%10.59K | -67.84%14.67K | 1,815.99%769.05K | 1,668.57%695K | 1,668.57%695K |
| Other revenue | 46.74%24.75M | 53.62%17.77M | 38.75%9.57M | 50.17%39.19M | -16.03%16.87M | -9.29%11.57M | -13.92%6.9M | -7.40%26.1M | 24.51%20.09M | 32.09%12.75M |
| Operating profit | -30.91%242.01M | -32.74%183.65M | -53.87%80.24M | 34.94%419.45M | -10.54%350.26M | -9.01%273.05M | 69.76%173.93M | -54.13%310.85M | -41.98%391.55M | -24.93%300.09M |
| Add:Non operating Income | 181.55%2.92M | 258.56%2.42M | -10.88%301.73K | -60.13%2.24M | -78.11%1.04M | -74.28%675.59K | -76.87%338.58K | 22.61%5.62M | 64.00%4.74M | 67.33%2.63M |
| Less:Non operating expense | -83.83%1.29M | -88.77%877.53K | -97.58%183.5K | -84.25%8.73M | -80.62%7.96M | -26.54%7.81M | 158.56%7.57M | 43.82%55.41M | 16.16%41.06M | 49.25%10.63M |
| Total profit | -29.04%243.64M | -30.35%185.2M | -51.80%80.35M | 58.19%412.96M | -3.35%343.34M | -8.96%265.91M | 65.06%166.69M | -59.45%261.06M | -44.70%355.23M | -25.90%292.08M |
| Less:Income tax cost | -18.07%34.1M | -7.67%29.01M | -42.15%7.31M | -76.11%46.82M | -75.43%41.62M | -63.46%31.43M | -63.46%12.64M | -21.60%195.96M | 16.14%169.38M | 9.87%86.01M |
| Net profit | -30.55%209.55M | -33.39%156.18M | -52.59%73.04M | 462.44%366.14M | 62.35%301.72M | 13.79%234.48M | 132.00%154.05M | -83.47%65.1M | -62.57%185.85M | -34.77%206.07M |
| Net profit from continuing operation | -30.55%209.55M | -33.39%156.18M | -52.59%73.04M | 287.97%252.56M | 62.35%301.72M | 13.79%234.48M | 132.00%154.05M | -83.47%65.1M | -62.57%185.85M | -34.77%206.07M |
| Net income from discontinuing operating | ---- | ---- | ---- | --113.58M | ---- | ---- | ---- | ---- | ---- | ---- |
| Less:Minority Profit | -39.73%38.38M | -34.33%28.94M | -43.35%14.01M | 219.47%62.75M | 98.58%63.69M | 161.15%44.06M | 22,723.38%24.72M | -38.42%19.64M | 586.95%32.07M | 249.96%16.87M |
| Net profit of parent company owners | -28.09%171.16M | -33.18%127.25M | -54.35%59.04M | 567.44%303.39M | 54.79%238.03M | 0.65%190.42M | 95.09%129.33M | -87.44%45.46M | -69.44%153.77M | -39.18%189.2M |
| Earning per share | ||||||||||
| Basic earning per share | -26.09%0.17 | -31.58%0.13 | -53.85%0.06 | 650.00%0.3 | 53.33%0.23 | 0.00%0.19 | 85.71%0.13 | -88.89%0.04 | -70.00%0.15 | -38.71%0.19 |
| Diluted earning per share | -26.09%0.17 | -31.58%0.13 | -53.85%0.06 | 650.00%0.3 | 53.33%0.23 | 0.00%0.19 | 116.67%0.13 | -88.57%0.04 | -69.39%0.15 | -36.67%0.19 |
| Other composite income | ||||||||||
| Total composite income | -30.55%209.55M | -33.39%156.18M | -52.59%73.04M | 462.44%366.14M | 62.35%301.72M | 13.79%234.48M | 132.00%154.05M | -83.47%65.1M | -62.57%185.85M | -34.77%206.07M |
| Total composite income of parent company owners | -28.09%171.16M | -33.18%127.25M | -54.35%59.04M | 567.44%303.39M | 54.79%238.03M | 0.65%190.42M | 95.09%129.33M | -87.44%45.46M | -69.44%153.77M | -39.18%189.2M |
| Total composite income of minority owners | -39.73%38.38M | -34.33%28.94M | -43.35%14.01M | 219.47%62.75M | 98.58%63.69M | 161.15%44.06M | 22,723.38%24.72M | -38.42%19.64M | 586.95%32.07M | 249.96%16.87M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Shanghui Certified Public Accountants (Special General Partnership) | -- | -- | -- | Shanghui Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CN
Overall
Symbol
Price
% Chg
No Data
